 The drug was developed by Sucampo Pharmaceuticals and approved by the Food and Drug Administration (FDA) in 2006.It was recommended for use in the UK by the National Institute for Health and Care Excellence (NICE) in July 2014.Health Canada approved the drug in 2015.